Although the canonical Wnt/beta-catenin pathway is upregulated in ALS (15–18), riluzole, an enhancer of this system (19) represents a classically prescribed treatment of this disease in humans. Here, CTNNB1 is linked to amyotrophic lateral sclerosis.